The company's liquidity is under extreme pressure, evidenced by a $74.6K operating cash flow deficit in 2026Q1 and a nominal cash balance of only $2,929 as of 2025Q4.
| Cash from Operations | -415.7K | -565.1K | -672.29K | 0 |
| Operating CF Growth % | 87.64% | 15.94% | - | - |
| Net Income | 920.55K | 1.06M | 2.55M | 171.39K |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.4M | -1.9M | -3.62M | -196.23K |
| Working Capital Changes | 68.63K | 270.66K | 392.5K | 24.84K |
| Cash from Investing | 32.72M | 63.58M | -277.7K | -69.69M |
| Purchase of Investments | 0 | 0 | 0 | -69.69M |
| Sale/Maturity of Investments | 0 | 0 | 0 | 0 |
| Net Investment Activity | 0 | 0 | 0 | -69.69M |
| Acquisitions | 0 | 0 | 0 | 0 |
| Other Investing | 32.72M | 63.58M | -277.7K | 0 |
| Cash from Financing | -32.3M | -63.04M | 397.48K | 70.27M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | -34.06M | -65.33M | 0 | 0 |
| Stock Issued | 0 | 0 | 0 | 70.27M |
| Net Stock Activity | -34.06M | -65.33M | 0 | 70.27M |
| Debt Issuance (Net) | 1.34M | 1000K | 277.7K | 0 |
| Other Financing | 426.88K | 539.82K | 119.78K | 0 |
| Net Change in Cash | 11.17K | -25.28K | -552.51K | 580.72K |
| Exchange Rate Effect | 0 | 0 | 0 | 0 |
| Cash at Beginning | 2.93K | 28.21K | 580.72K | 0 |
| Cash at End | 18.52K | 2.93K | 28.21K | 580.72K |
| Interest Paid | 0 | 0 | 0 | 0 |
| Income Taxes Paid | 0 | 0 | 0 | 0 |
| Free Cash Flow | -415.7K | -565.1K | -672.29K | 0 |
| FCF Growth % | 43% | 15.94% | - | - |
Immediate going concern liquidity
According to recent SEC filings, AFJK's inability to generate positive operating cash flow, which reached a deficit of $74.6K in 2026Q1, underscores the firm's total reliance on external financing to sustain its administrative overhead and maintain its public listing status as a pre-revenue shell entity.
The consistent negative operating cash flow relative to net income suggests that the company lacks any organic capital generation capacity. Investors should monitor the reliance on short-term debt, which appears to be the primary mechanism for funding ongoing operational expenses in the absence of revenue.
As reported in financial statements, AFJK has recorded zero investment activity since the $69.7M outflow in 2023Q4, indicating that the entity has ceased all asset acquisition efforts and is currently operating as a passive shell with no active deployment of capital into the biopharmaceutical sector.
The lack of investment activity suggests that the company is not currently pursuing growth through asset accumulation. This stagnation may indicate that management is either unable to source viable targets or is conserving the remaining $2,929 in cash to cover essential regulatory and compliance costs.
Based on the company's reported figures, AFJK has engaged in significant share buybacks totaling $65.4M across 2025, a move that appears highly incongruous with its current cash-constrained position and suggests a potential depletion of capital that could have otherwise supported the entity's stated acquisition objectives.
The decision to execute large buybacks while operating cash flow remains negative warrants further investigation into the company's capital allocation strategy. Such actions may indicate a lack of alignment between management's financial decisions and the long-term viability of the shell as a merger vehicle.
Data from the most recent quarterly reports indicates that AFJK has increasingly relied on short-term debt, with balances rising to $68.7K in 2026Q1, which may indicate that the company is masking its underlying liquidity crisis through temporary financing rather than sustainable operational cash flow generation.
The reliance on short-term debt to bridge the gap between operating expenses and cash reserves suggests a precarious financial position. Analysts should consider that the reported cash balance of $2,929 may be insufficient to cover upcoming liabilities, potentially necessitating further dilutive financing or sponsor-led capital injections.
Quick answers to the most common questions about buying AFJK stock.
Aimei Health Technology Co., Ltd (AFJK) generated $-0.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Aimei Health Technology Co., Ltd (AFJK) reported negative free cash flow of $0.6M in 2025, indicating capital requirements exceeded cash from operations.
Aimei Health Technology Co., Ltd (AFJK) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Aimei Health Technology Co., Ltd (AFJK) spent $65.3M on share repurchases. This shows the company's commitment to returning capital to its equity investors.